Movement Disorders Feature Archive
Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.
The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.
The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
More than half of patients diagnosed with Parkinson disease experience freezing of gait.
Surgical interventions for Parkinson disease are experiencing a swell in innovation, thanks in part to the entry of two additional medical device companies into a field previously dominated by one company.
In this article, we explore research findings to provide a deeper understanding of the factors associated with increased risk for impulse control disorders in Parkinson disease. Deputy Director of the Parkinson's UK charity, Professor David Dexter, also provides insights on the mechanisms of impulse control disorders and the implications of new findings on the management of Parkinson disease.
Although deep brain stimulation, similar to all Parkinson disease therapies, cannot cure, modify, or slow progression of the disease, some recent research suggests that the symptom alleviation and quality-of-life improvement it provides might lead to mild improvements in longevity.
"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.
Parkinsonism syndromes are associated with progressive disability and increased mortality, with symptom burden comparable to that of advanced cancer.
Anesthetic medications have been identified as a potential cause of morbidity in this population due to their interaction with the drugs used to manage Parkinson disease.
Several studies have uncovered sex-dependent variations in the symptomatic manifestations of Parkinson disease, as well as in the response to dopamine therapies.
Numerous factors are likely contribute to the rate of progression, with different combinations of factors showing relevance for individual patients.
Although evidence of cognitive impairment in MSA is admittedly more limited than in Parkinson disease, it is now substantial enough to address modification of diagnostic criteria to include the potential for cognitive impairment at any stage of the disease.
While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.
Research has shown significant gaps in knowledge on palliative services among neurology residents, resulting in low referral rates.
There is speculation that dystonia is the result of dysfunction occurring in either the cerebellum or basal ganglia or as a result of an abnormal interaction between the two.
MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.
The main challenge is to determine when treating tardive dyskinesia with any pharmacological agent would provide a net benefit.
Debate continues as to whether ocular tremor represents a clinical marker of Parkinson's disease or a compensatory movement related to other bodily tremors.
Investigators identified a series of prodromal signs that appear anywhere from 1 to 18 years before a clinical diagnosis of SCA2.
New guidelines for progressive supranuclear palsy provide very specific and sensitive criteria that allow for identification of clinical features of the disease at much earlier stages.
A patient should be notified of the possibility of developing an ICD before initiating any dopaminergic treatment for PD, particularly dopamine agonists.
Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.
Research has shown a confounding link between nicotine and reduced risk of Parkinson's disease.
Parkinson's disease psychosis is underreported and is difficult to treat, but a new drug in late-stage development is a promising therapy.
The ongoing INTREPID clinical trial is evaluating the safety and effectiveness of the Vercise™ DBS System.
The role of GCH1 mutations in Parkinson's disease is complicated by the mutation's seemingly exclusive role in dopa-responsive dystonia.
Closed-loop neurostimulation technology is being investigated for movement disorders, headache, and even some neuropsychiatric disorders.
Motion-sensing technology provides a lot of data, but researchers still aren't sure if it's clinically useful.
Several anti-diabetes agents hold promise for Parkinson's disease-related neurodegeneration.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- CBD Superior to Placebo, Similar to AEDs for Managing Epilepsy Syndromes
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Hydrocephalus May Be a Complication of Congenial Zika Syndrome
- Higher CSF NfL Protein Levels Linked to Risk for Mild Cognitive Impairment
- Addressing Cognitive Impairment in Pediatric MS: Expert Q&A
- How the Government Shutdown Affects FDA Activities